270 related articles for article (PubMed ID: 32945980)
1. The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia.
Penson PE; Banach M
Curr Atheroscler Rep; 2020 Sep; 22(11):67. PubMed ID: 32945980
[TBL] [Abstract][Full Text] [Related]
2. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
[TBL] [Abstract][Full Text] [Related]
3. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel.
Cicero AFG; Colletti A; Bajraktari G; Descamps O; Djuric DM; Ezhov M; Fras Z; Katsiki N; Langlois M; Latkovskis G; Panagiotakos DB; Paragh G; Mikhailidis DP; Mitchenko O; Paulweber B; Pella D; Pitsavos C; Reiner Ž; Ray KK; Rizzo M; Sahebkar A; Serban MC; Sperling LS; Toth PP; Vinereanu D; Vrablík M; Wong ND; Banach M
Nutr Rev; 2017 Sep; 75(9):731-767. PubMed ID: 28938795
[TBL] [Abstract][Full Text] [Related]
4. Treatment and Low-Density Lipoprotein Cholesterol Management in Patients Diagnosed With Clinical Atherosclerotic Cardiovascular Disease in Alberta.
Chen G; Farris MS; Cowling T; Colgan SM; Xiang P; Pericleous L; Rogoza RM; Tai MH; Anderson T
Can J Cardiol; 2019 Jul; 35(7):884-891. PubMed ID: 31292087
[TBL] [Abstract][Full Text] [Related]
5. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
6. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
7. Atherosclerotic Cardiovascular Disease in Women: Providing Protection With Lipid-altering Agents.
Hiles M; Simmons A; Hilleman D; Gibson CA; Backes JM
Clin Ther; 2023 Nov; 45(11):1127-1136. PubMed ID: 37770308
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects.
Duprez DA; Handelsman Y; Koren M
Vasc Health Risk Manag; 2020; 16():403-418. PubMed ID: 33116551
[TBL] [Abstract][Full Text] [Related]
9. Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.
Berman AN; Blankstein R
Curr Cardiol Rep; 2019 Aug; 21(9):110. PubMed ID: 31378838
[TBL] [Abstract][Full Text] [Related]
10. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
11. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
[TBL] [Abstract][Full Text] [Related]
12. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP
Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086
[TBL] [Abstract][Full Text] [Related]
13. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
14. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
[TBL] [Abstract][Full Text] [Related]
15. A Clinical Guide to Combination Lipid-Lowering Therapy.
Russell C; Sheth S; Jacoby D
Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
[TBL] [Abstract][Full Text] [Related]
16. A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence.
Barrios V; Escobar C; Cicero AF; Burke D; Fasching P; Banach M; Bruckert E
Atheroscler Suppl; 2017 Feb; 24():1-15. PubMed ID: 27998714
[TBL] [Abstract][Full Text] [Related]
17. Nonstatin therapies for management of dyslipidemia: a review.
Sando KR; Knight M
Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
[TBL] [Abstract][Full Text] [Related]
18. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
[TBL] [Abstract][Full Text] [Related]
19. Best practice for treating dyslipidaemia in patients with diabetes based on current international guidelines.
Lan NSR; Burns K; Bell DA; Watts GF
Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):104-113. PubMed ID: 33278128
[TBL] [Abstract][Full Text] [Related]
20. Approach to the Patient With a Suboptimal Statin Response: Causes and Algorithm for Clinical Management.
Sun L; Wolska A; Amar M; Zubirán R; Remaley AT
J Clin Endocrinol Metab; 2023 Aug; 108(9):2424-2434. PubMed ID: 36929838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
